Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
NCT02117817 · Rutgers, The State University of New Jersey · PHASE1 · withdrawn · last registry update 2022-07-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Research cancelled” | – | Registry record, Rutgers, The State University of New Jersey |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-04-27Also stopped (withdrawn): Roswell Park Cancer Institute, Buparlisib + Cisplatin (NCT01971489)
- 2022-12-28Results posted on the registry: National Cancer Institute (NCI), Taselisib (NCT04439175)
- 2022-08-22Also stopped (terminated): Vanderbilt-Ingram Cancer Center, Enzalutamide + Taselisib (NCT02457910)
- 2022-08-16Phase 3 first posted: Celcuity Inc, Gedatolisib + Palbociclib (NCT05501886)
- 2022-07-12Also stopped (terminated): Hoffmann-La Roche, Taselisib + Placebo (NCT02340221)
- 2022-05-18Also stopped (terminated): SignalRX Pharmaceuticals, Inc., SF1126 + Nivolumab (NCT03059147)
- 2022-02-01Results posted on the registry: US Oncology Research, BKM120 + capecitabine (NCT02000882)
- 2021-10-11Also stopped (terminated): Prince of Songkla University, BKM120 (NCT01806649)
- 2021-10-07Results posted on the registry: Pfizer, PF-05212384 (gedatolisib) + Docetaxel (NCT01920061)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision